Clinical experience with ranolazine in a veteran population with chronic stable angina;Expérience Clinique avec la Ranolazine chez une Population de Vétérans Souffrant d'Angine Chronique Stable

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 42-50

  Reeder, Don N ^a   Gillette, Michael A ^b   Franck, Andrew J ^c   Frohnapple, David J ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Malcom Randall Veterans Affairs Medical Center   (United States)

^d TOTAL   (France)

Author keywords

Angina pectoris; Chronic stable angina; Drug toxicity; Ranolazine; Veterans

Indexed keywords

DILTIAZEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANOLAZINE; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLURRED VISION; CHRONIC DISEASE; CLINICAL ARTICLE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART INFARCTION; HUMAN; MALE; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM; STABLE ANGINA PECTORIS; STROKE; VETERAN; XEROSTOMIA;

ACETANILIDES; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGINA, STABLE; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROGLYCERIN; PIPERAZINES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS; VETERANS;

EID: 84855692713     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q487     Document Type: Article

References (36)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
2. Fraker TD Jr, Fihn SD; 2002 Chronic Stable Angina Writing Committee; American College of Cardiology; American Heart Association, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007;50:2264-74 (erratum 2007;50:e1).
3. Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med 2009;169:1491-9. DOI 10.1001/archinternmed.2009.295
4. Gibbons RJ, Abrams J, Chatterjee K, et al. American College of Cardiology/ American Heart Association 2002 guideline update for the management of patients with chronic stable angina. www.acc.org/qualityandscience/clinical/statements.htm (accessed 2011 Aug 8).
5. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009;2:344-53. DOI 10.1161/CIRCOUTCOMES.108.829523
6. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina: observations from the randomized, doubleblind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-6.
7. Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med 1998;158:626-632. DOI 10.1001/archinte.158.6.626
8. Randall M, Kilpatrick KE, Pendergast JF, et al. Differences in patient characteristics between Veterans Administration and community hospitals: implications for VA planning. Med Care 1987;25:1099-110.
9. Wolinsky FD, Coe RM, Mosely RR, Homan SM. Veterans' and nonveterans' use of health services: a comparative analysis. Med Care 1985;23:1358-71.
10. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989;262:907-13. DOI 10.1001/jama.262.7.907
11. Kazis LE, Ren XS, Lee A, et al. Health status in VA patients: results from the Veterans Health Study. Am J Med Qual 1999;14:28-38. DOI 10.1177/106286069901400105
12. Greene RS, Rangel RM, Edwards KL, et al. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med 2011 Aug 17. [Epub ahead of print] DOI 10.1016/j.carrev.2011.06.001
13. Wiest FC, Bryson CL, Burman M, et al. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med 2004;117:234-41. DOI 10.1016/j.amjmed.2004.02.044
14. Package insert. Ranexa (ranolazine). Palo Alto, CA: CV Therapeutics, Inc., 2006.
15. Sossalla ST, Mazur M, Kallmeyer B, et al. Effects of the novel antiischemic agent ranolazine on contractility and arrhythmias in human atrial myocardium. Clin Res Cardiol 2009;98:1-2.
16. Na using ranolazine. J Cardiovasc Pharmacol 2009;54:279-86. DOI 10.1097/FJC.0b013e3181a1b9e7
17. Antzelevich C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10. DOI 10.1161/01.CIR.0000139333.83620.5D
18. Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The antiischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol 2010;56:934-42. DOI 10.1016/j.jacc.2010.04.042
19. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet 2008;372:1335-41. DOI 10.1016/S0140-6736(08)61554-8
20. Dobesh PP, Trujillo TC. Ranolazine: a new option in the management of chronic stable angina. Pharmacotherapy 2007;27:1659-76. DOI 10.1592/phco.27.12.1659
21. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. DOI 10.1016/j.jacc.2003.11.045
22. Chaitman B, Pepine C, Parker J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-16. DOI 10.1001/jama.291.3.309
23. Stone P, Gratsiansky N, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 2006;48:566-75.
24. Trujillo TC, Dobesh PP. Traditional management of chronic stable angina. Pharmacotherapy 2007;27:1677-92. DOI 10.1592/phco.27.12.1677
25. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med 2005;352:2524-33. Review (erratum 2005;353:2728).
26. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333-41. DOI 10.1016/0735-1097(94)00397-9
27. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994;74:1240-4. DOI 10.1016/0002-9149(94)90555-X
28. Drew BJ, Ackerman MJ, Funk M, et al. American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing; American College of Cardiology Foundation. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:934-47. DOI 10.1161/CIRCULATIONAHA.109.192704
29. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008;359:677-87.
30. Wyrwich KW, Spertus JA, Kroenke K, et al. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J 2004;147:615-22.
31. Thygesen K, Alpert JS, White HD, et al., on behalf of the Joint European Society of Cardiology/American College of Cardiology Foundation/ American Heart Association/World Heart Foundation Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
32. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83.
33. Rifkin SI. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape J Med 2008;10:264.
34. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006;45:469-91.
35. Jerling M, Huan B, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33.
36. Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health Syst Pharm 2010;67:1829-31.